Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of breast cancer susceptibility protein (BRCA)-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Sambade, Maria J, Van Swearingen, Amanda E D, McClure, Marni B, Deal, Allison M, Santos, Charlene, Sun, Kaiming, Wang, Jing, Mikule, Keith, Anders, Carey K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212882/
https://ncbi.nlm.nih.gov/pubmed/32642648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados